


PEOPLE WITH DIABETES ARE NOT USING A POTENTIALLY LIFE-CHANGING STANDARD OF CARE WHEN MANAGING THEIR CONDITION

Time in range* is a modern diabetes management metric that can be measured by a real time continuous glucose monitoring system (rt-CGM). Spending more time in range has the potential to improve the lives of people with diabetes, **but more than half of people with insulin-treated diabetes aren't using it.**¹




SPENDING MORE TIME IN RANGE CAN OFFER QUALITY OF LIFE BENEFITS THAT CAN'T BE IGNORED

When people with insulin-treated diabetes spend more time in range



People with insulin-treated diabetes




said they would rather swim with sharks than go low during an important meeting or event¹



More than half agree that if they were able to spend more time in range, they'd feel more confident to pursue their dreams or passions¹

DESPITE THESE BENEFITS, TIME IN RANGE ISN'T WIDELY USED BY PEOPLE WITH INSULIN-TREATED DIABETES



While the majority are aware of what time in range is and its advantages as a metric to gauge treatment success¹



More than half do not use time in range as a metric to gauge treatment success¹

EVERYONE HAS A ROLE IN STARTING THE CONVERSATION ABOUT TIME IN RANGE



Nearly two-thirds of people with insulin-treated diabetes believe it is the responsibility of their healthcare professional to bring new standards of care to their attention¹



Less than a quarter of people with insulin-treated diabetes say they regularly discuss time in range with their healthcare professional¹

"I believe I deserve the most cutting-edge technology available to manage my disease."



70% believe they deserve the best technology¹

*Defined by the International Consensus on Time in Range as 70-180 mg/dL [3.9-10.0 mmol/L] at least 70% of the time. Consult with your HCP/Healthcare Professional to determine your individual target range.

¹ Dexcom, U.K. data on file, July 2021.

² Perera et al. 2018

About the Data

The research was conducted by Censuswide, with 1,006 People living with insulin treated diabetes aged 18+ in the UK (n=403), Denmark (n=101), Sweden (n=201), Australia (n=201) & Netherlands (n=100) – ensuring 50% Type 1 and 50% type 2 with the following quotas for age (quotas are per market): Type 1 Insulin using – 50%, Age: 18-39 – 42%, 40-59 – 50%, 60+ – 8%. Type 2 Insulin using – 50%, Age: 18-39 – 13%, 40-59 – 48%, 60+ – 39%

Research was conducted between 30th June and 30th July 2021. Censuswide abide by and employ members of the Market Research Society which is based on the ESOMAR principles.

The Global Movement for Time in Range is the result of collaboration between Dexcom, Inc., Nick Jonas, Beyond Type 1, JDRF, College Diabetes Network, Taking Control of Your Diabetes and Children with Diabetes.